Welcome to our dedicated page for BeOne Medicines Ltd. SEC filings (Ticker: BEIGF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on BeOne Medicines Ltd.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into BeOne Medicines Ltd.'s regulatory disclosures and financial reporting.
BeOne Medicines Ltd. SVP and general counsel Lee Chan Henry exercised options for 21,697 ordinary shares on July 22, 2026, at exercise prices of $14.96, $16.41 and $12.23 per share. He acquired American Depositary Shares at prices of $194.47, $213.32 and $159.03 per ADS, and sold 1,669 ADS at $325 pursuant to a Rule 10b5-1 trading plan adopted on May 29, 2026. After these transactions he held 338,884 ordinary shares directly.
BeOne Medicines Ltd. director and Chief Executive Officer John Oyler exercised share options covering 441,870 Ordinary Shares at an exercise price of $9.23 per share and on the same date acquired 33,990 American Depositary Shares through an exercise or conversion transaction at $119.96 per ADS.
On July 20–21, 2026, he sold an aggregate 109,713 American Depositary Shares in multiple open-market or private transactions at weighted-average prices within ranges from $309.39 to $320.39 per ADS under a Rule 10b5-1 trading plan adopted on March 10, 2026. After these trades he reported 4,461,518 Ordinary Shares held directly, plus additional Ordinary Shares held indirectly through various trusts and entities, some of which he disclaims beneficial ownership. Each American Depositary Share represents 13 Ordinary Shares.
ONC reports that a holder working with Morgan Stanley Smith Barney LLC Executive Financial Services plans to sell 2,001 ADS on NASDAQ on 07/22/2026, with the sale tied to an exercise of stock options for cash. The notice also lists prior 10b5-1 plan sales by Chan Lee over the past three months, including 664 ADS for 200833.44 on 07/08/2026, 871 ADS for 235539.14 on 06/08/2026, and 332 ADS for 103159.04 on 05/13/2026.
BeOne Medicines Ltd. director and CEO John Oyler exercised options to acquire 64,628 American Depositary Shares (ADS), representing 840,164 Ordinary Shares, at $119.96 per ADS, and then sold 64,628 ADS in multiple open-market transactions at weighted-average prices, with execution prices ranging from $304.96 to $315.18 per ADS, pursuant to a Rule 10b5-1 trading plan adopted on March 10, 2026. Following these transactions, he directly holds 5,445,917 Ordinary Shares, and the filing also lists substantial indirect holdings in various trusts and Oyler Investment LLC, for which beneficial ownership is disclaimed, as well as 9,545,000 Ordinary Shares held for his benefit in a Roth IRA.
BeOne Medicines Ltd. CEO John Oyler exercised options to acquire 283,154 American Depositary Shares (ADS) and sold the same number on July 15–16, 2026 at weighted average prices from $310.0201 to $323.5858 per ADS under a Rule 10b5-1 trading plan adopted March 10, 2026.
After the trades, he reported no directly held ADS and held 5,445,917 ordinary shares directly as of July 15, 2026, plus indirect positions via trusts and an IRA, including holdings for which he disclaims beneficial ownership, and 1,282,034 share options with a $9.23 exercise price.
BeOne Medicines Ltd. Chief Executive Officer John Oyler reported both option exercises and share sales. On July 14, 2026 he exercised options covering 1,736,800 ordinary shares and sold 145,861 American Depositary Shares at prices between $302.48 and $307.87 per ADS under a Rule 10b5-1 trading plan. After these transactions he holds 5,445,917 ordinary shares directly, additional indirect interests through trusts and a Roth IRA, and 462,866 remaining share options.
BeOne Medicines Ltd. CEO John Oyler exercised options for 60,218 American Depositary Shares at $36.90 and sold 60,218 ADS in open‑market trades in July 2026 at weighted‑average prices between $295.66 and $307.44 under a Rule 10b5‑1 plan, leaving no directly held ADS. The filing also lists 5,605,310 ordinary shares held directly as of July 10, 2026 and additional ordinary shares recorded as indirectly held through various trusts and a Roth IRA, with beneficial ownership disclaimed for several trust positions.
Holders of ONC securities filed notice of a proposed sale of 513,574 ADS through Morgan Stanley Smith Barney LLC Executive Financial Services, with an aggregate market value of $156,105,953.04, expected to trade on NASDAQ on July 14, 2026.
The ADS relate to 425,590 ADS from stock options exercised on July 14, 2026, 75,723 ADS from stock options previously exercised on March 3, 2025, and 12,261 ADS from restricted stock units dated June 5, 2026. Separately, 54,885,669 ADS were outstanding; this is a baseline figure, not the amount being sold. Recent 10b5-1 plan sales by John Oyler, the Pan-Oyler Foundation and John V. Oyler covered ADS and common shares on several dates in June and July 2026.
BeOne Medicines Ltd. senior vice president and general counsel Lee Chan Henry reported option exercises and an associated sale of American Depositary Shares (ADSs). On July 8, 2026, he exercised options to acquire multiple blocks of ADSs and sold 664 ADSs at $302.46 per ADS in an open-market transaction pursuant to a pre-arranged Rule 10b5-1 trading plan. Following these transactions, he held 338,884 Ordinary Shares directly, and continued to hold several option positions over Ordinary Shares with stated exercise prices and future expiration dates.
ONC filed to potentially sell 150,000 ADS on 07/10/2026 through Morgan Stanley Smith Barney LLC Executive Financial Services on NASDAQ. The ADS were acquired via an exercise of stock options for cash from the issuer. In the past three months, reporting person John V. Oyler sold common shares in several transactions, including 3,410 shares for $933,592.21 on 06/23/2026 and 4,940 shares for $1,336,566.40 on 06/08/2026.